247 related articles for article (PubMed ID: 32972614)
1. Proposed use of thalidomide for the cytokine storm of COVID-19.
Goihman-Yahr M
Clin Dermatol; 2020; 38(4):508. PubMed ID: 32972614
[No Abstract] [Full Text] [Related]
2. Alternative management of Covid-19 infection.
Atrah HI
Scott Med J; 2020 Aug; 65(3):72-75. PubMed ID: 32638647
[TBL] [Abstract][Full Text] [Related]
3. Purposing Saikosaponins for the treatment of COVID-19.
Bahbah EI; Negida A; Nabet MS
Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
[No Abstract] [Full Text] [Related]
4. Thalidomide Should Be Tested as a Therapeutic Option in COVID-19 Pneumonia.
Tiscornia JE; Poggio TV; Feinsilber DG; Coleman AE
Skinmed; 2020; 18(4):254-255. PubMed ID: 33050993
[No Abstract] [Full Text] [Related]
5. Dapsone and doxycycline could be potential treatment modalities for COVID-19.
Farouk A; Salman S
Med Hypotheses; 2020 Jul; 140():109768. PubMed ID: 32339778
[No Abstract] [Full Text] [Related]
6. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
Dal Moro F; Livi U
Clin Immunol; 2020 May; 214():108414. PubMed ID: 32272196
[No Abstract] [Full Text] [Related]
7. May IL-17 have a role in COVID-19 infection?
Megna M; Napolitano M; Fabbrocini G
Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777
[No Abstract] [Full Text] [Related]
8. Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report.
Gonzales-Zamora JA; Quiroz T; Vega AD
Medwave; 2020 Aug; 20(7):e7998. PubMed ID: 32876623
[TBL] [Abstract][Full Text] [Related]
9. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19.
Mrityunjaya M; Pavithra V; Neelam R; Janhavi P; Halami PM; Ravindra PV
Front Immunol; 2020; 11():570122. PubMed ID: 33117359
[TBL] [Abstract][Full Text] [Related]
10. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
11. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
Almerie MQ; Kerrigan DD
Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
[TBL] [Abstract][Full Text] [Related]
12. COVID-19: Some clinical questions after the first 4 months.
Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
[No Abstract] [Full Text] [Related]
13. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
14. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
Abdulrab S; Al-Maweri S; Halboub E
Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
[No Abstract] [Full Text] [Related]
15. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
Jiménez-Brítez G; Ruiz P; Soler X
Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713
[No Abstract] [Full Text] [Related]
17. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
Henderson LA; Canna SW; Schulert GS; Volpi S; Lee PY; Kernan KF; Caricchio R; Mahmud S; Hazen MM; Halyabar O; Hoyt KJ; Han J; Grom AA; Gattorno M; Ravelli A; De Benedetti F; Behrens EM; Cron RQ; Nigrovic PA
Arthritis Rheumatol; 2020 Jul; 72(7):1059-1063. PubMed ID: 32293098
[TBL] [Abstract][Full Text] [Related]
18. Immune-Mediated Coagulopathy in COVID-19 Infection.
Vadasz Z; Brenner B; Toubi E
Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
[No Abstract] [Full Text] [Related]
19. Tocilizumab administration in a refractory case of COVID-19.
Dastan F; Nadji SA; Saffaei A; Tabarsi P
Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
[No Abstract] [Full Text] [Related]
20. Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Zhou H; Fang Y; Xu T; Ni WJ; Shen AZ; Meng XM
Br J Pharmacol; 2020 Jul; 177(14):3147-3161. PubMed ID: 32368792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]